Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.07. | IMAC Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.07. | IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors | 1 | GlobeNewswire (USA) | ||
02.07. | IMAC Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
18.06. | IMAC Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.06. | IMAC Holdings files to sell common stock and warrants, size not disclosed | 2 | Seeking Alpha | ||
13.06. | IMAC Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
24.05. | IMAC Holdings appoints Faith Zaslavsky as CEO | 2 | Seeking Alpha | ||
24.05. | IMAC Holdings, Inc.: IMAC Holdings Announces Leadership Succession | 1 | GlobeNewswire (USA) | ||
24.05. | IMAC Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.05. | IMAC Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
15.05. | IMAC Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
07.05. | IMAC Holdings, Inc.: IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business | 170 | GlobeNewswire (Europe) | FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ: BACK)... ► Artikel lesen | |
03.05. | IMAC Holdings Inc expected to post a loss of 91 cents a share - Earnings Preview | 2 | Reuters | ||
02.05. | IMAC Holdings, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
01.05. | IMAC Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
19.04. | (BACK) - Analyzing IMAC Holdings' Short Interest | 2 | Benzinga.com | ||
19.04. | Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers | 3 | Seeking Alpha | ||
17.04. | IMAC Holdings Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
16.04. | IMAC Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
16.04. | IMAC Holdings, Inc. - 10-K, Annual Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PLUS THERAPEUTICS | 1,690 | -2,76 % | Plus Therapeutics Inc.: Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference | ||
ASENSUS SURGICAL | 0,299 | -3,92 % | Asensus Surgical, Inc.: Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology | RESEARCH TRIANGLE PARK, N.C., July 23, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced... ► Artikel lesen | |
INVIVO THERAPEUTICS HOLDINGS | 0,200 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.02.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 23.02.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.02.2024.ISIN NameCA58503M4083 MEDIVOLVE... ► Artikel lesen | |
MEDIVOLVE | 0,003 | 0,00 % | Medivolve Inc (2): Medivolve changes auditor to MS Partners | ||
REWALK ROBOTICS | 4,078 | 0,00 % | ReWalk Robotics Ltd. (LFWD): A Good Robotic Stock Under $10? | ||
EKSO BIONICS | 1,200 | +5,26 % | Ekso Bionics Holdings, Inc.: Ekso Bionics to Report Second Quarter 2024 Financial Results on July 29, 2024 | ||
IMUNON | 1,120 | -2,61 % | Imunon, Inc.: IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer | Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.... ► Artikel lesen | |
AVINGER | 1,440 | -11,66 % | Avinger, Inc.: Avinger Announces Closing of up to $24 Million Public Offering | $6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series WarrantsREDWOOD CITY, CA / ACCESSWIRE / June 17, 2024... ► Artikel lesen | |
ROCKWELL MEDICAL | 1,787 | +1,59 % | Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance | WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis... ► Artikel lesen | |
VIRIDIAN THERAPEUTICS | 15,300 | -0,65 % | Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results | WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare... ► Artikel lesen | |
SINTX TECHNOLOGIES | 5,300 | +6,64 % | SINTX Technologies, Inc.: SINTX Technologies to Explore Strategic Opportunities | Salt Lake City, Utah., June 18, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company") today announced that its Board of Directors has initiated a process to explore... ► Artikel lesen | |
AETHLON MEDICAL | 0,354 | +5,36 % | Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update | Conference Call to be Held Today at 4:30 p.m. ET
SAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to... ► Artikel lesen | |
STAGEZERO LIFE SCIENCES | 0,028 | 0,00 % | StageZero Life Sciences Ltd: StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order | TORONTO, ON / ACCESSWIRE / July 9, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene... ► Artikel lesen | |
NEURONETICS | 1,698 | +0,83 % | Neuronetics: Aetna Policy Update Expands TMS Availability for Adolescents With Depression | ||
ARCH THERAPEUTICS | - | - | Arch Therapeutics, Inc. - 8-K, Current Report |